Paris, 13 December 2007 – Hybrigenics and L’Oréal are working together to know more about certain kin and hair proteins and to discover innovative substances: following the discovery of new interactions between skin proteins, a chemical screening has been carried out to identify small molecules able to inhibit one of these interactions, as part of L'Oréal's scientific research for innovative cosmetics.
|
|
Hybrigenics provides protein interaction screening and analysis tools for Genethon’s muscle cell program
2005 December - Hybrigenics, the pathway-based drug discovery company, today announces that Genethon, the gene and cell therapy research and application center, will use Hybrigenics’ Yeast Two-Hybrid Screening platform and its Protein Interaction Mapping software in a new program of research into muscle cell proteins and their interaction. The program will allow a better understanding of the muscle and the development of new therapeutic leads. |
|
Hybrigenics obtains worldwide certification for its proteomics services
2005 May - Hybrigenics, the protein pathway based drug discovery company, has obtained worldwide quality certification for its proteomics services. These include the coveted ISO 9001-2000 European certification, the QMI in the USA and the JQA in Japan. |
|
A protein interaction map for a better insight in cancer development
2005 February - With the completion of the genome sequence of a number of organisms, analysis of the gene products, the proteins, is the on-going challenge. Researchers from the Institut Curie and from the Paris-based biotechnology company Hybrigenics announced today that they have built a protein-protein interaction map of the fruit fly, Drosophila melanogaster. This ‘simple’ model organism allows them to study a ‘reference set’ of proteins that includes most of those known to be involved in human cancer. Since proteins function in networks, the systematic identification of the physical interactions that occur between proteins will help understanding their biological function, and improve our capacity to intervene and, ultimately, to discover novel, more specific therapeutic targets. Their results are published in the March 1st issue of Genome Research. |
|
|
